

HEPATTS S

(GIT block, Microbiology: 2019)

By: Dr. Malak M. El-Hazmi

Associate professor & Consultant Virologist College of Medicine &

King Saud University Medical City

OBJECTIVES;

viruses causing entericaly transmitted hepatitis

HAV. HEV.

viruses that are causing
 hepatitis during their course of infection;
 e.g Cytomegalovirus (CMV)
 Epstein-Barr virus (EBV)
 Arbovirus (yellow fever virus)

- structure
- Epidemiology
- clinical presentations
- Lab diagnosis
- > Treatment
- prevention

HEPATITIS

Viral hepatitis

- As part of generalized infection (CMV, EBV, Yellow fever virus)
- Infect primarily the liver
 - Faecal-borne hepatitis (A & E)
 - Blood-borne hepatitis (B, C & D)

FECAL-BORNE HEPATITS

- **HAV**
- Picornaviridae


- **HEV**
- Hepeviridae

- **4**Nonenveloped
- #Icosahedral
- **♣ss,**+ sense RNA
- **4**One serotype

HEPATITIS A VIRUS

Hepatitis A

Short incubation hepatitis
Infectious hepatitis
Epidemic hepatitis




#Epidemiology



- Distribution:
 - a worldwide, endemic in tropical countries
- Transmission:
 - Faecal-oral route [major route]
 Contaminated food &water
 - Sexual contact (homosexual men)
 - Blood transfusion (v.rarely)
- Age:
 - In developing countries; children*
 - In developed countries; young adults


#Pathogenesis





- CMI Damage of virus-infected hepatocyte
 - ALT ,AST & Bilirubin





Manifestations



Hepatitis

- IP=2-6 Ws
- Pre-icteric phase: fever, fatique, N, V,& RUQP
- Icteric phase: dark urine, pale stool, jaundice





- Asymptomatic & anicteric inf —> common
- Symptomatic illness —> † age



#Prognosis

- Self-limited disease
- Fulminant hepatitis rare
- Mortality rate ~ 0.1 0.3%
- No chronicity or malignancy changes



#Lab. Diagnosis

Serology:

- Anti-HAV IgM —— Current inf
- Anti-HAV IgG previous inf
 - ----> immunity

4Management



- Treatment:
 - Supportive therapy
- Prevention:
 - Sanitation & hygiene measures
 - HIg
 - Vaccine



4Prevention

HIg:

- Given before or within 2 Ws of exposure
- Indication: travelers unvaccinated, exposed p

4Prevention



Vaccine:

- inactivated
- Given IM at [0,6-12 M]
- ♣ >1 Y of age
- S/E: mild local reaction



P at high risk of severe dis

4A combination vaccine (HAV &HBV)



HEPATITIS E VIRUS

- Hepeviridae
- Epidemiology:
- outbreak of waterborne & sporadic cases of VH
- Age; young adults
- 4 routes of transmission;
 - Waterborne*
 - Zoonotic foodborne
 - Bloodborne
 - Perinatal

HEPATITIS E VIRUS

Clinical features:

- ~ HAV infection & exceptions:
 - Longer IP =4-8 Ws
 - Chronic hepatitis and cirrhosis (not HCC)
 - Fulminant disease
 - Mortality rate ~10 times > HAV
 - ~ (1-3%)
 - ~ 20% in pregnancy

HEPATITIS E VIRUS

- Lab diagnosis:
 - ELISA —— Anti-HE IgM
- Treatment:
 - Not specific
- Prevention:
 - Sanitation & hygiene measures
 - No Ig
 - No vaccine

FECAL-BORNE HEPATITS

VIRAL HEPATITIS: A GLOBAL VIEW

SIX WAYS TO HELP PREVENT HEPATITIS A & E

Talk to your doctor about the hepatitis A vaccine



2



Cook food well & eat it while it's hot Avoid raw shellfish and raw meat



4

Always wash hands with soap & water after using the toilet, changing a diaper, and before preparing & eating food 5

Peel fruit & vegetables and wash salads in clean water



6 Only drink safe water



Source: Based on information from the World Health Organization

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation. The Cigna name, logo and other Cigna marks are owned by Cigna Intellectual Property, Inc.

This material is provided for informational/educational purposes only. It is not intended as medical/clinical advice.



Herpesviridae

1-Herpes simplex virus type -1

2-Herpes simplex virus type -2

3-Varicella –Zoster virus

4-Epstein-Barr virus

5-Cytomegalovirus

6-Human herpes virus type-6

7-Human herpes virus type-7

8-Human herpes virus type-8

HSV-1

HSV-2

VZV

EBV

CMV

HHV-6

HHV-7

HHV-8



dsDNA, Icosahedral & Enveloped Virus



<u> Epstein – Barr Virus EBV</u>

- > It is lymphotropic.
- > It has oncogenic properties;

Burkitt's lymphoma Nasopharyngeal carcinoma

Epidemiology

- Distribution :worldwide
- Transmission:
 - Saliva [kissing disease]
- Age:

Socio-economic status: SE


- Low SE class early childhood

Clinical Features:



1-Immunocompetent host

- Asymptomatic
- Infectious mononucleosis [glandular fever]
 - Mainly in teenagers & young adults
 - \triangleright IP = 4-7 weeks
 - Complications(acute air way obstruction, splenic rupture, CNS inf)
- Chronic EBV infection




2- Immunocompromised host

Lymphoproliferative disease (LD)

Dx: Hematology:

■ Î WBC

lymphocytosis
(Atypical lymphocytes)




Serology:

- Non-specific AB test;
 - Heterophile Abs +ve

EB\

Paul-Bunnell or mono-spot test



EBV-specific AB test:
 IgM Abs to EBV capsid antigen



Management:

- > Treatment:
 - Antiviral drug is not effective in IMN
- > Prevention:
 - No vaccine

Cytomegalovirus CMV

- Special features ;
- Infected cell enlarged with multinucleated.
 - [cyto=cell, megalo=big]
- Resistant to acyclovir.
- Latent in monocyte ,lymphocyte & other .

- Distribution: worldwide .
- Transmission;
 - Early in life:
 - Transplacental
 - Birth canal
 - Breast milk
 - Young children: saliva
 - Later in life: sexual contact
 - Blood transfusion & organ transplant .



Acquired Infections;

- Immunocompetent host
 - Asymptomatic
 - Self-limited illness
 - Hepatitis
 - Infectious mononucleosis like syndrome [Heterophile AB is –ve]
- Immunocompromised host
 - Encephalitis, Retinitis, Pneumonia,
 - Hepatitis*, Esophagitis, Colitis

Congenital Infections:

Lab. Dx



* Histology:

Intranuclear inclusion bodies

[Owl's -eye]

* Culture:

In human fibroblast

 $1-4 \text{ wks} \implies \text{CPE}$


► Shell Vial Assay → 1-3 days

* Serology:

 \rightarrow AB \Longrightarrow IgM : current inf

→ IgG: previous exposure

► Ag CMV pp65 Ag by IFA






Fig. 2, CMV centrifugation culture fixed and stained 16 hrs after inoculation showing viral proteins in nuclei of infected human fibroblast cells



Rx.




- Ganciclovir
 - is effective in the Rx of severe CMV inf.
- Foscarnet: the 2nd drug of choice.


Prevention:

- Screening;
 - Organ donors
 - Organ recipients
 - Blood donors
- Leukocyte-depleted blood.
- Prophylaxis: Ganciclovir, CMVIG.
- No vaccine.

<u>Arthropod – borne Viruses</u> (Arboviruses) <u>Yellow Fever virus</u>

- > Flaviviridae
- ➤ Asymptomatic to Fever ± Jaundice ± hemorrhage ± renal failure
- EpidemiologyTropical Africa& South America
 - 1. Jungle Yellow Fever
 - 2. Urban Yellow Fever





Jungle Yellow Fever:

- Vector: mosquito
- Reservoir: Monkey
- Accidental host:human
- It is a disease of Monkeys

Urban Yellow Fever:

- Vector: mosquito
- Reservoir: human
- It is a disease of humans



- Lab. Methods:
 - A- Isolation
 - B IgM -AB* ELISA, IF: (most used)
 - C YFV- RNA by RT-PCR

Prevention


1-Vector Control:

- Elimination of vector breading sites
- Using insecticides
- Avoidance contact with vectors

(repellants, net)

2-Vaccine:

Yellow Fever vaccine (LAV, one dose /10 yrs)





Reference books

Review of Medical Microbiology and Immunology.

By: Warren Levinson.


14th Edition, 2014.

<u>Medical Microbiology.</u>

By: David Greenwood, Richard Slack,

John Peutherer and Mike Barer.

17th Edition, 2007.





Thank you